Nav: Home

New drug combinations help overcome resistance to immunotherapy

May 28, 2020

FINDINGS

A new study from researchers at the UCLA Jonsson Comprehensive Cancer Center helps explain how disruptions in genes can lead to the resistance to one of the leading immunotherapies, PD-1 blockade, and how new drug combinations could help overcome resistance to the anti-PD-1 therapy in a mechanistically-based way.

The team found changing the tumor microenvironment with toll-like receptor 9 agonists made up of sequences of nucleic acids that mimic a bacterial infection, as well as another immunotherapy drug NKTR-214 that stimulates a natural killer cell response, can help induce a potent immune reaction that enables the immune system to more effectively attack resistant tumors. When these drugs were given in combination with PD-1 blockade, they were able to overcome genetic immunotherapy resistance in preclinical models.

BACKGROUND

The development of immunotherapies, like PD-1 blockade, has changed the landscape of cancer therapy. It is extremely effective for a substantial number of patients, even those with lethal tumors. Despite its success in treating people with deadly forms of cancer, there are still many people who do not benefit from the treatment or eventually experience a relapse of their cancer. Various combinations of PD-1 blockade with other therapies are being investigated, but there is currently no easy way to identify which therapeutic agents can best improve immune response on underlying mechanisms involving resistance to PD-1 blockade. UCLA researchers have been seeking ways to better understand the biology of resistance mechanisms to develop rationally advanced combinatorial therapies to overcome this resistance.

METHOD

Using CRISPR/Cas9 genome editing, the team created genetic resistant models of JAK1, JAK2 and B2M mutations by gene knockout in human and murine cell lines. They studied functional mechanisms involved in interferon-gamma signaling changes in human melanoma cell lines and in mouse models of cancer that were found to led to resistance to anti-PD-1 therapy. Based on the molecular understanding of these pathways, the team then tested strategies to overcome resistance in two mouse models of anti-PD-1 immunotherapy. They then tested in mice rationally designed combinatorial treatments to describe the best choices of combined therapy based on these mechanisms of acquired resistance.

IMPACT

Identifying how to improve the immune response on underlying mechanisms involving immunotherapy resistance has the potential to improve the antitumor activity of cancer immunotherapy and provide more therapies to more patients with hard-to-treat cancers. The combination therapies of PD-1 blockade with NKTR-214 or toll-like receptor 9 that were identified in the study are now being assessed in human clinical trials for patients whose tumors have not responded to anti-PD-1 therapy.
-end-
AUTHORS

The study's lead author is Dr. Davis Torrejon, a postdoctoral researcher in the division of Hematology/Oncology at the David Geffen School of Medicine at UCLA. The senior author is Dr. Antoni Ribas, professor of medicine and director of the tumor immunology program at the UCLA Jonsson Comprehensive Cancer Center. A full list of authors can be found in the journal article.

JOURNAL

The study was published in Cancer Discovery, a journal of the American Association for Cancer Research.

FUNDING

The research was funded in part by the Parker Institute for Cancer Immunotherapy, the Young Investigator Award from American Society of Clinical Oncology and grants from the National Institutes of Health.

The UCLA Jonsson Comprehensive Cancer Center has more than 500 researchers and clinicians engaged in cancer research, prevention, detection, control, treatment and education. One of the nation's largest comprehensive cancer centers, the UCLA Jonsson Comprehensive Cancer Center is dedicated to promoting research and translating basic science into leading-edge clinical studies.

University of California - Los Angeles Health Sciences

Related Cancer Articles:

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
Health indicators for newborns of breast cancer survivors may vary by cancer type
In a study published in the International Journal of Cancer, researchers from the UNC Lineberger Comprehensive Cancer Center analyzed health indicators for children born to young breast cancer survivors in North Carolina.
Few women with history of breast cancer and ovarian cancer take a recommended genetic test
More than 80 percent of women living with a history of breast or ovarian cancer at high-risk of having a gene mutation have never taken the test that can detect it.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Our Relationship With Water
We need water to live. But with rising seas and so many lacking clean water – water is in crisis and so are we. This hour, TED speakers explore ideas around restoring our relationship with water. Guests on the show include legal scholar Kelsey Leonard, artist LaToya Ruby Frazier, and community organizer Colette Pichon Battle.
Now Playing: Science for the People

#568 Poker Face Psychology
Anyone who's seen pop culture depictions of poker might think statistics and math is the only way to get ahead. But no, there's psychology too. Author Maria Konnikova took her Ph.D. in psychology to the poker table, and turned out to be good. So good, she went pro in poker, and learned all about her own biases on the way. We're talking about her new book "The Biggest Bluff: How I Learned to Pay Attention, Master Myself, and Win".
Now Playing: Radiolab

Uncounted
First things first: our very own Latif Nasser has an exciting new show on Netflix. He talks to Jad about the hidden forces of the world that connect us all. Then, with an eye on the upcoming election, we take a look back: at two pieces from More Perfect Season 3 about Constitutional amendments that determine who gets to vote. Former Radiolab producer Julia Longoria takes us to Washington, D.C. The capital is at the heart of our democracy, but it's not a state, and it wasn't until the 23rd Amendment that its people got the right to vote for president. But that still left DC without full representation in Congress; D.C. sends a "non-voting delegate" to the House. Julia profiles that delegate, Congresswoman Eleanor Holmes Norton, and her unique approach to fighting for power in a virtually powerless role. Second, Radiolab producer Sarah Qari looks at a current fight to lower the US voting age to 16 that harkens back to the fight for the 26th Amendment in the 1960s. Eighteen-year-olds at the time argued that if they were old enough to be drafted to fight in the War, they were old enough to have a voice in our democracy. But what about today, when even younger Americans are finding themselves at the center of national political debates? Does it mean we should lower the voting age even further? This episode was reported and produced by Julia Longoria and Sarah Qari. Check out Latif Nasser's new Netflix show Connected here. Support Radiolab today at Radiolab.org/donate.